fbpx
Wikipedia

TMC-310911

TMC-310911 (also known as ASC-09) is an antiviral drug which was originally researched as a treatment for HIV/AIDS. It is a protease inhibitor related to darunavir.[1][2] While TMC-310911 was not ultimately developed as a medication for the treatment of AIDS, research has continued into potential applications in the treatment of other viral diseases, and in March 2020 it was entered into clinical trials for the treatment of COVID-19.[3][4]

TMC-310911
Legal status
Legal status
  • US: Investigational drug
Identifiers
  • [(3As,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[[2-[(1-cyclopentylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
CAS Number
  • 1000287-05-7
PubChem CID
  • 53361968
DrugBank
  • DB15623
ChemSpider
  • 34554561
UNII
  • 0151W500HP
Chemical and physical data
FormulaC38H53N5O7S2
Molar mass755.99 g·mol−1
3D model (JSmol)
  • Interactive image
  • CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7
  • InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1
  • Key:JQUNFHFWXCXPRK-AMMMHQJVSA-N

See also edit

References edit

  1. ^ Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G (December 2011). "TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors". Antimicrobial Agents and Chemotherapy. 55 (12): 5723–31. doi:10.1128/AAC.00748-11. PMC 3232804. PMID 21896904.
  2. ^ Ghosh AK, Brindisi M (April 2015). "Organic carbamates in drug design and medicinal chemistry". Journal of Medicinal Chemistry. 58 (7): 2895–940. doi:10.1021/jm501371s. PMC 4393377. PMID 25565044.
  3. ^ Catapang JK, Billones JB (March 2020). "On the Generation of Novel Ligands for SARS-CoV-2 Protease and ACE2 Receptor via Constrained Graph Variational Autoencoders". ChemRxiv. doi:10.26434/chemrxiv.12011157.v3.
  4. ^ McGrath J (2 April 2020). "All the COVID-19 vaccines and treatments currently in clinical trials". Digital Trends. Retrieved 6 April 2020.

310911, also, known, antiviral, drug, which, originally, researched, treatment, aids, protease, inhibitor, related, darunavir, while, ultimately, developed, medication, treatment, aids, research, continued, into, potential, applications, treatment, other, vira. TMC 310911 also known as ASC 09 is an antiviral drug which was originally researched as a treatment for HIV AIDS It is a protease inhibitor related to darunavir 1 2 While TMC 310911 was not ultimately developed as a medication for the treatment of AIDS research has continued into potential applications in the treatment of other viral diseases and in March 2020 it was entered into clinical trials for the treatment of COVID 19 3 4 TMC 310911Legal statusLegal statusUS Investigational drugIdentifiersIUPAC name 3As 4R 6aR 2 3 3a 4 5 6a hexahydrofuro 2 3 b furan 4 yl N 2S 3R 4 2 1 cyclopentylpiperidin 4 yl amino 1 3 benzothiazol 6 yl sulfonyl 2 methylpropyl amino 3 hydroxy 1 phenylbutan 2 yl carbamateCAS Number1000287 05 7PubChem CID53361968DrugBankDB15623ChemSpider34554561UNII0151W500HPChemical and physical dataFormulaC 38H 53N 5O 7S 2Molar mass755 99 g mol 13D model JSmol Interactive imageSMILES CC C CN C C H C H CC1 CC CC C1 NC O O C H 2CO C H 3 C H 2CCO3 O S O O C4 CC5 C C C4 N C S5 NC6CCN CC6 C7CCCC7InChI InChI 1S C38H53N5O7S2 c1 25 2 22 43 23 33 44 32 20 26 8 4 3 5 9 26 41 38 45 50 34 24 49 36 30 34 16 19 48 36 52 46 47 29 12 13 31 35 21 29 51 37 40 31 39 27 14 17 42 18 15 27 28 10 6 7 11 28 h3 5 8 9 12 13 21 25 27 28 30 32 34 36 44H 6 7 10 11 14 20 22 24H2 1 2H3 H 39 40 H 41 45 t30 32 33 34 36 m0 s1Key JQUNFHFWXCXPRK AMMMHQJVSA NSee also editBrecanavir TMC 647055References edit Dierynck I Van Marck H Van Ginderen M Jonckers TH Nalam MN Schiffer CA Raoof A Kraus G Picchio G December 2011 TMC310911 a novel human immunodeficiency virus type 1 protease inhibitor shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors Antimicrobial Agents and Chemotherapy 55 12 5723 31 doi 10 1128 AAC 00748 11 PMC 3232804 PMID 21896904 Ghosh AK Brindisi M April 2015 Organic carbamates in drug design and medicinal chemistry Journal of Medicinal Chemistry 58 7 2895 940 doi 10 1021 jm501371s PMC 4393377 PMID 25565044 Catapang JK Billones JB March 2020 On the Generation of Novel Ligands for SARS CoV 2 Protease and ACE2 Receptor via Constrained Graph Variational Autoencoders ChemRxiv doi 10 26434 chemrxiv 12011157 v3 McGrath J 2 April 2020 All the COVID 19 vaccines and treatments currently in clinical trials Digital Trends Retrieved 6 April 2020 Retrieved from https en wikipedia org w index php title TMC 310911 amp oldid 1215136392, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.